Long-term smallcap play, Clarity Pharmaceuticals (ASX:CU6)Clarity is a clinical-stage radiopharmaceutical company developing targeted theranostics — drugs that combine diagnostic imaging and therapy — using copper isotopes (Cu-64 and Cu-67).
SAR-bisPSMA: A dual-function radiopharmaceutical targeting PSMA for both imaging (with 64Cu) and therapy (with 67Cu) in prostate cancer. Est. market entry 2026-2027
SAR-Bombesin: Targets the gastrin-releasing peptide receptor (GRPR) for imaging and treatment of GRPR-positive cancers, including prostate and breast cancers. Est. market entry 2027-2028
SARTATE: Designed for diagnosing and treating neuroblastoma and neuroendocrine tumors using copper isotopes. Est. market entry 2028+
SAR-trastuzumab: A preclinical radioimmunotherapy combining trastuzumab with Clarity’s SAR Technology to target HER2-positive breast cancer. Est. market entry 2030+
